Mukka Proteins Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2026.
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 0.3 pts less than its Animal Feed peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mukka Proteins reported strong full-year FY26 consolidated results with total income of ₹14,781.35 million (up ~44% YoY) and revenue from operations at ₹14,035.15 million (up ~43% YoY from ₹9,800.26 million). Net profit after tax stood at ₹570.86 million (standalone: ₹424.12 million), growing ~19% on consolidated basis. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. The Board approved raising ₹75 crore via secured NCD issuances (₹25 crore + ₹50 crore) on a private placement basis. New investments include a 51% stake in partnership firm MPL FC HRC JV (₹2.55 lakh capital contribution) and incorporation of an overseas entity Lanka Bio Proteins Private Limited in Sri Lanka (₹2.5 crore for 49% stake). Operating cash flow remained deeply negative at –₹1,112.65 million (consolidated) driven by a massive ₹2,923 million surge in inventories. Total borrowings grew sharply to ₹7,677.70 million (standalone: ₹6,699.87 million), reflecting aggressive working capital and capex buildup.
Revenue growth is impressive at ~43%, but the sharp rise in borrowings and persistent negative operating cash flow raise concerns about liquidity risk. The NCD issuance of ₹75 crore signals ongoing funding needs. Shareholders should watch inventory buildup and debt levels closely as the company scales operations.